Relmada Therapeutics, Inc. (RLMD) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
2222 Ponce de Leon Blvd.
Coral Gables, FL 33134
United States of America (the)
Phone
786 629 1376
Website
Sector
Healthcare
Industry
Biotechnology
Employees
17
First IPO Date
June 20, 2014
| Name | Title | Pay | Year Born |
| Sergio Traversa | Chief Executive Officer & Director | 3.94M | 1960 |
| Paul E. Kelly | Chief Operating Officer & Director | 1.96M | 1957 |
| Charles S. Ence | Chief Accounting & Compliance Officer | 2.17M | 1965 |
| Maged S. Shenouda | Chief Financial Officer | 2.64M | 1964 |
| Richard Mangano | Consultant | 0 | 1950 |
| Raj S. Pruthi | Chief Medical Officer of Urology | 0 | 1967 |
| Andrew Cutler | Senior Clinical Development Advisor | 0 | N/A |
| Gina DiGuglielmo | Vice President & Head of Clinical Operations | 0 | N/A |
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.